HPV vaccination of immunocompromised hosts
AuthorGarland, SM; Brotherton, JML; Moscicki, AB; Kaufmann, AM; Stanley, M; Bhatla, N; Sankaranarayanan, R; de Sanjose, S; Palefsky, JM
Source TitlePapillomavirus Research
PublisherELSEVIER SCIENCE BV
AffiliationMelbourne School of Population and Global Health
Obstetrics and Gynaecology
Document TypeJournal Article
CitationsGarland, S. M., Brotherton, J. M. L., Moscicki, A. B., Kaufmann, A. M., Stanley, M., Bhatla, N., Sankaranarayanan, R., de Sanjose, S. & Palefsky, J. M. (2017). HPV vaccination of immunocompromised hosts. PAPILLOMAVIRUS RESEARCH, 4, pp.35-38. https://doi.org/10.1016/j.pvr.2017.06.002.
Access StatusOpen Access
It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References